Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etoposide + Bevacizumab + QL1706 in Platinum-Resistant Ovarian Cancer
NCT07117877Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Sep 2025
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in ovarian cancer, sponsored by Fudan University. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07117877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07117877.